Check out the “Resources” section of this website for more details, but the quick answer is “yes”. Cannabis, and THC from cannabis, has been shown to have beneficial properties related to seizure disorders, anxiety, and many, many other conditions.
Lexaria CanPharm Corp was incorporate in Canada in 2014 as a wholly-owned subsidiary to its parent company Lexaria Biosciences Corp, which is a publicly traded company in both the USA and Canada. Lexaria CanPharm Corp. is focused on only the global cannabis industry and has no other business interests, and holds the exclusive global rights to utilize Lexaria’s DehydraTECH technology for delivery of cannabis not including hemp.
The global legal cannabis industry is growing dramatically. Eight Capital of Toronto estimates a global market of over $100 billion; whereas Grand View Research estimates it at US$146 billion by 2025. The legal cannabis industry expects growth from two major areas: one is the conversion of current illegal use to legal and in which nations that will occur – it is impossible to forecast how rapidly consumers in different geographical locations will make that change. The other area of growth is the expansion of cannabis users from historical customers who defied laws banning its use, to more mainstream and socially acceptable use of cannabis in non-smoked social settings.
Lexaria CanPharm Corp does not grow cannabis; nor do we extract oils or byproducts from the cannabis plant or make or sell consumer products that contain THC. Instead we focus on the difficult “last mile” problem: how to maximize the absorption into the human bloodstream of a difficult-to-absorb set of molecules. Lexaria’s technology works with EVERY cannabis extract that we’ve tested; it delivers cannabinoids more quickly and more effectively regardless of which manufacturer utilizes our tech. We believe this means that whether it is a cannabis extract, a capsule or pill, or even an FDA-regulated cannabidiol based drug – in every instance our tech helps deliver more of what the consumer is paying for.
Lexaria’s DehydraTECHTM technology is patent-granted in the USA and Australia for the delivery of cannabinoids and other substances and drugs. It is patent-pending in over 40 other countries around the word. Lexaria Cannabis Corp holds the exclusive global license from its parent company Lexaria Bioscience Corp, for commercial opportunities related to cannabis delivery that utilizes DehyraTECH. Lexaria’s intellectual property is quite strong and includes composition of matter patents as well as process patents. As of September, 2018 there are over 50 Lexaria patents pending and an expectation that there will be more than 100 patents pending by the end of 2019.